MGH researchers uncover potential antiviral drug target for treating infectious diseases
The UAB team looked at inpatient surgical records for 34,042 patients between January 2017 and October 2018. That time period covered eight months when surgical jackets and bouffants were not required, six months when surgical jackets were required, and eight months when both surgical jackets and bouffants were required.
The authors report no significant difference in the risk of surgical site infections, mortality or postoperative sepsis during the three different time periods. The cost of the single-use surgical jackets at UAB during the study period was more than $300,000. The authors estimate that the use of surgical jackets alone in all United States hospitals would cost the health care system $540 million annually.
The results of this study suggest that surgical jackets and bouffants are neither beneficial nor cost-effective in preventing SSIs. Surgical site infections are a significant complication, and hospitals and health care providers are diligently looking for ways to reduce the risk of infection. Our data add support to the growing body of literature suggesting that the well-intentioned recommendations on surgical jackets and bouffants have not been shown to have an effect on SSIs." Brent Ponce, M.D., professor in the Department of Orthopaedic Surgery at UAB and senior author of the study
The authors say the first step in reducing infections is to understand the potential sources of infection. Other measures include maintaining a sterile surgical field, limiting operating room traffic, reducing surgical time and better management of patient's comorbidities prior to surgery.
There are an estimated 300,000 SSIs annually in the United States, accounting for approximately 20 percent of all hospital-acquired infections and increasing hospital length of stay by an average of 9.7 days. Source:
University of Alabama at Birmingham Journal reference:
Wills, B.W., et al. (2020) Association of Surgical Jacket and Bouffant Use With Surgical Site Infection Risk. JAMA Surgery . doi.org/10.1001/jamasurg.2019.6044 .
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology